Eli Lilly and Company completed its acquisition of AtaiBeckley Inc. on 2026-09-11, according to the Form 8-K AtaiBeckley Inc. filed with the SEC on 2026-09-11. The filing's Item 2.01 states no aggregate dollar price. AtaiBeckley Inc. filed the report because the deal made it part of Eli Lilly and Company.
| Acquirer | Eli Lilly and Company |
|---|---|
| Acquired | AtaiBeckley Inc. |
| Completed | 2026-09-11 |
| Reported by | AtaiBeckley Inc. (ATAI), the company acquired |
| Filing | Form 8-K, filed 2026-09-11 |
Want the whole picture on Eli Lilly and Company?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Eli Lilly and Company: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Eli Lilly and Company covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
1 cited source found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
What the filing says
On September 11, 2026 (the " Closing Date "), pursuant to the Merger Agreement, Merger Sub merged with and into the Company (the " Merger "), with the Company surviving as a wholly owned subsidiary of Parent.
More from the filing
As previously disclosed in the Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission (the " SEC ") on July 16, 2026, AtaiBeckley Inc. (the " Company ") entered into an Agreement and Plan of Merger, dated as of July 15, 2026 (the " Merger Agreement "), with Eli Lilly and Company, an Indiana corporation (" Parent "), and Albali Acquisition Corporation, a Delaware corporation and indirect wholly owned subsidiary of Parent (" Merger Sub ").
Capitalized terms used herein and not otherwise defined herein have the meanings set forth in the Merger Agreement.
Pursuant to the Merger Agreement, and upon the terms and subject to the conditions thereof, at the effective time of the Merger (the " Effective Time ") each share of the Company's common stock, par value $0.01 per share (the " Common Stock "), issued and outstanding immediately prior to the Effective Time (other than (x) shares held in the treasury of the Company, owned by the Company or any of its subsidiaries, or owned by Parent, Merger Sub or any of their wholly owned subsidiaries, and (y) Dissenting Shares (as defined in the Merger Agreement)) was converted into the right to receive (i) $
Quoted from AtaiBeckley Inc.'s Form 8-K.
Other acquisitions by Eli Lilly and Company
| Completed | Acquired | Price stated |
|---|---|---|
| 2025-11-07 | Adverum Biotechnologies, Inc. | Not stated |
| 2026-03-04 | Ventyx Biosciences, Inc. | $1.2 billion |
Who runs it now, who owns it, where the money comes from and what to watch for, every claim linked to its source.
Order Full Report on Eli Lilly and CompanyLook up Eli Lilly and Company and see what is on record before you decide.
Get the free SnapshotWhere this comes from
A public company must file a current report on Form 8-K with the SEC within four business days of completing a significant acquisition or disposition of assets, under Item 2.01 of the report. The acquired company sometimes files one too, when the deal makes it a subsidiary of the buyer.
Every fact on this page is taken from one of those filings and linked to it: which company acquired which, the date the filing gives for completion, and the price when the filing states one in dollars, shown next to the sentence that states it. A filing states what was bought and on what terms; it rarely states why, and neither does this page.